Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
PROK Stock Chart & Stats
$2.57
-$0.14(-7.65%)
At close: 4:00 PM EST
$2.57
-$0.14(-7.65%)
Day’s Range― - ―
52-Week Range$0.46 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)1.42M
Market Cap
$773.14M
Enterprise Value$1.39B
Total Cash (Recent Filing)$271.73M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding141,545,440
10 Day Avg. Volume1,082,632
30 Day Avg. Volume1,420,820
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)-0.17
Price to Sales (P/S)2177.35
P/FCF Ratio-1.06
Enterprise Value/Market Cap1.79
Enterprise Value/Revenue1.86K
Enterprise Value/Gross Profit-2.12K
Enterprise Value/Ebitda-9.27
Forecast
1Y Price Target
$2.00Price Target Upside-22.18% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMore than half of the patients needed for the accelerated approval analysis of PROACT 1 have been enrolled.
Financial StabilityProKidney Corp ended the quarter with cash and equivalents of $294.7 million, supporting its operations into mid-2027.
Regulatory ProgressFDA has confirmed that PROACT 1 can also serve as the confirmatory trial for rilparencel.
Bears Say
Clinical RiskAnalyst heavily risk adjusts Phase 3 success due to the absence of a sham and a small representative patient population in previous studies.
Market ConcernsAnalyst maintains an Underperform rating and $1 price objective due to concerns around trial risk and a potentially niche end-market.
Valuation ConcernsReiterate Neutral rating on PROK shares based on valuation and potential of rilparencel balanced with the need for more de-risking on biology and clinical aspects.
ProKidney News
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $0.46 and its highest was $7.13 in the past 12 months.
What is ProKidney’s market cap?
ProKidney’s market cap is $773.14M.
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is May 08, 2026 which is in 153 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Nov 18, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.013.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Overvalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ProKidney have?
ProKidney has 141,545,440 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went up 1.754%.
Which hedge fund is a major shareholder of ProKidney?
Currently, no hedge funds are holding shares in PROK
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$2.00 (-22.18% Downside)
$2.00 (-22.18% Downside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.94%
Trailing 12-Months
Company Description
ProKidney
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$2.00
▼(-22.18% Downside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
Currently, No data available
---